Skip to main content

Table 4 Changes in baseline to endpoint measures for lipid profile in two groups

From: Randomized double blind clinical trial evaluating the Ellagic acid effects on insulin resistance, oxidative stress and sex hormones levels in women with polycystic ovarian syndrome

Variables Mean ± SD
Placebo(n = 28)
Mean ± SD
Ellagic acid (n = 29)
P1
Chol(mg/dL) Baseline 192 ± 51.03 197.13 ± 48.71 0.801
End 190.28 ± 58.51 178.09 ± 45.46 0.024
P2 0.754 0.0349  
Mean Changes -1.72 ± 7.48 -19.04 ± 3.25 0.031
TG (mg/dL) Baseline 159.19 ± 19.61 163.28 ± 20.55 0.586
End 157.2 ± 19.29 145.33 ± 16.04 0.042
P2 0.59 0.04  
Mean Changes -1.99 ± 0.32 -17.95 ± 4.51 0.043
HDL (mg/dL) Baseline 37.08 ± 6.27 36.13 ± 7.7 0.55
End 37 ± 6.25 39.2 ± 8.02 0.124
P2 0.61 0.082  
Mean Changes -0.08 ± 0.02 3.07 ± 0.32 0.23
LDL (mg/dL) Baseline 123.08 ± 40.05 128.34 ± 36.89 0.714
End 122.28 ± 44.11 108.7 ± 35.19 0.04
P2 0.8 0.031  
Mean Changes -0.8 ± 4.06 -19.64 ± 1.7 0.044
  1. Data are expressed as means ± SD. Chol Cholesterol, TG Triglyceride, HDL High-Density lipoprotein, LDL Low-density lipoprotein
  2. P1: Comparison of the mean of lipid profile between the two groups of Ellagic acid and placebo (Independent samples t-test)
  3. P2: Comparison of mean of lipid profile in each group at baseline and end of study (Paired samples t-test)